Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Indian Pediatrics|February 25, 2014
Implementation of a pediatric rapid response team: experience of the Hospital for Sick Children in TorontoV Kukreti, R Gaiteiro, H Mohseni-Bod
Current Oncology (Toronto, Ont.)|August 5, 2014
Computerized prescriber order entry in the outpatient oncology setting: from evidence to meaningful useV Kukreti, R Cosby, A Cheung, et al.
Current Oncology (Toronto, Ont.)|January 5, 2017
Treatment and outcomes for primary cutaneous extramedullary plasmacytoma: a case seriesD S Tsang, L W Le, V Kukreti, et al.
Bone Marrow Transplantation|October 28, 2014
Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agentsV H Jimenez-Zepeda, D E Reece, S Trudel, et al.
Current Oncology (Toronto, Ont.)|April 26, 2014
Toward successful migration to computerized physician order entry for chemotherapyJ Jeon, S Taneva, V Kukreti, et al.
Bone Marrow Transplantation|January 20, 2015
CyBorD induction therapy in clinical practiceN Areethamsirikul, E Masih-Khan, C-M Chu, et al.
Bone Marrow Transplantation|October 7, 2014
Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failureR St Bernard, L Chodirker, E Masih-Khan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trialK Davison, B E Chen, V Kukreti, et al.
Leukemia|February 20, 2009
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trialC B Reeder, D E Reece, V Kukreti, et al.
Leukemia|May 15, 2013
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 studyA J Jakubowiak, D S Siegel, T Martin, et al.
Pageof 1